Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development

Int J Environ Res Public Health. 2022 Mar 31;19(7):4156. doi: 10.3390/ijerph19074156.

Abstract

Multiple illness is an increasingly common phenomenon. Its consequence is the need for polytherapy, which is particularly common among people suffering from arterial hypertension. The development of combined preparations (containing at least two API-active pharmaceutical ingredients) dedicated to the treatment of hypertension is a response to increased compliance, especially in elderly patients. In our work, we describe in particular the possibilities of using β-adrenergic receptors blockers and angiotensin-converting enzyme inhibitors in combinations. The combinations of APIs are used as single pills in patients with arterial hypertension with concomitant diseases such as hyperlipidemia; blood coagulation problems and diabetes mellitus were also discussed successively. Pharmacoeconomic analysis for the API combinations shown is also presented. As a final conclusion, numerous benefits of using the combined preparations should be indicated, especially by the elderly and/or in patients with coexistence of other diseases.

Keywords: ACE inhibitors; beta-blockers; fixed-dose combination; hypertension; single-pill combination.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents* / therapeutic use
  • Blood Pressure
  • Drug Industry
  • Drug Therapy, Combination
  • Humans
  • Hypertension* / drug therapy

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents